(INNL) (INNL) Stock Price, News & Analysis

Company Overview

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Key Stats

• Today's Range: $2.35 to $2.35
• 50-Day Range: N/A
• 52-Week Range: $0.53 to $6.51
• Volume: N/A
• Average Volume: 867,012 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INNL Stock Analysis - Frequently Asked Questions

How were (INNL)'s earnings last quarter?

(INNL) (NASDAQ:INNL) announced its quarterly earnings data on Wednesday, August, 17th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.11. The specialty pharmaceutical company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.04 million.

What other stocks do shareholders of (INNL) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (INNL) investors own include uniQure (QURE), Delcath Systems (DCTHD), NightHawk Biosciences (NHWK), LadRx (CYTR), Eleven Biotherapeutics (EBIO), Immune Pharmaceuticals (IMNP) and Neovasc (NVCN).

Company Calendar

• Last Earnings: 8/17/2016
• Today: 6/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INNL
• CIK: 1660484
• Web: www.innocoll.com
• Phone: +353-90-6486834
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A